Skip to content
OpenCapital
Get started

Chemed CHE Pre-tax stock-based compensation cost

Other financials

Income statement

See full
Revenue$657.5M+1.6%
Gross profit$215.8M-0.3%
Operating income$84.6M-10.7%
Net income$66.3M-7.6%
EPS (diluted)$4.84-0.4%

Balance sheet

See full
Cash & equivalents$16.9M-90.3%
Total debt$236.9M+63.3%
Total equity$848.0M-28.2%
Total assets$1.5B-11.0%

Cash flow

See full
Operating cash flow$88.2M+169%
CapEx$17.1M+28.9%
Free cash flow$71.1M+265%

Valuation

See full
Market cap$5.79B-42.3%
Enterprise value$6.01B-39.6%
P/E22.3×-10.2×
P/S2.3×-1.8×

Profitability

See full
Gross margin32.4%-2.4pp
Operating margin12.9%-2.7pp
Net margin10.2%-2.2pp
FCF margin14.8%+2.2pp

Returns & leverage

See full
Return on equity25.6%-0.5pp
Debt / equity0.3×+0.2×
Current ratio0.9×-0.9×

Where this comes from

Reported directly by Chemed in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: Chemed’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Chemed's pre-tax stock-based compensation cost.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Chemed's pre-tax stock-based compensation cost?
Chemed (CHE) reported pre-tax stock-based compensation cost of $9.67M in Q4 2025.
How has Chemed's pre-tax stock-based compensation cost changed year-over-year?
Chemed's pre-tax stock-based compensation cost decreased by 25.8% year-over-year, from $13.03M to $9.67M.
What is the long-term trend for Chemed's pre-tax stock-based compensation cost?
Over 4 years (2021 to 2025), Chemed's pre-tax stock-based compensation cost has grown at a 5.3% compound annual growth rate (CAGR), from $31.42M to $38.68M.